Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

Hedwig M. Blommestein*, Nigel Armstrong, Steve Ryder, Sohan Deshpande, Gill Worthy, Caro Noake, Rob Riemsma, Jos Kleijnen, Johan L. Severens, Maiwenn J. Al

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)23-31
Number of pages9
JournalPharmacoeconomics
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 2016

Keywords

  • LENALIDOMIDE
  • Best Suoortive Care
  • Evidence Review Group
  • Acute Myeloid Leukemia
  • Appraisal Committee

Cite this